LITERATURE
原始候选快照
v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。
| 论文 | 标识 | 日期 | 入排置信度 | 入排依据 | KM 状态 |
|---|---|---|---|---|---|
| Long-term safety and efficacy of ponesimod in participants with relapsing multiple sclerosis: results from the phase 3 OPTIMUM 5-year long term extension study.J Neurol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:Fig. 1:图注未提示 KM 曲线;Fig. 2:图注未提示 KM 曲线;Fig. 3:图注未提示 KM 曲线;Fig. 4:图注未提示 KM 曲线;Fig. 5:图注未提示 KM 曲线。 | PMID 41879928PMC13018072 | 2026-Mar-25 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy and Safety of NFL-101 as a Smoking Cessation Therapy: A Randomized Phase II Clinical Trial CESTO2.Nicotine Tob Res入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 40884488PMC13008582 | 2026-Mar-24 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Concizumab in hemophilia with inhibitors: longer-term efficacy and safety results from the phase 3 explorer7 study.Blood Adv疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Figure 1:图注未提示 KM 曲线;Figure 1.:非 KM 图;Figure 2.:图注未提示 KM 曲线。 | PMID 41499759PMC12993885 | 2026-Mar-24 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Fluconazole plus flucytosine versus fluconazole alone for adults with HIV-associated cryptococcal antigenaemia identified through screening: a multi-centre phase III randomised-controlled trial.Trials疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41877274PMC13134226 | 2026-Mar-24 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Perfluorohexyloctane eye drops in treating dry eye disease associated with meibomian gland dysfunction: a post hoc analysis by baseline severity.Int Ophthalmol入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 41870723PMC13009075 | 2026-Mar-23 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial.LancetPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41765029无 PMCID | 2026-Mar-21 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Low-concentration bimatoprost 0.01% and timolol 0.1% eye gel versus bimatoprost 0.03% and timolol 0.5% eye drops in open-angle glaucoma or ocular hypertension: a phase III randomised study.Br J Ophthalmol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:Figure 1:非 KM 图;Figure 2:森林图/亚组分析图;Figure 3:图注未提示 KM 曲线;Figure 4:图注未提示 KM 曲线。 | PMID 41093358PMC13018773 | 2026-Mar-20 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Pharmacodynamics of Camizestrant Treatment in Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer: Results From the Randomized, Presurgical SERENA-3 Study.J Clin Oncol入排复审未纳入:The study is an oncology randomized trial with a drug intervention and original results, but it does not have a primary or key secondary time-to-event efficacy endpoint. Its primary endpoints are pharmacodynamic (ER expression, Ki67) from a presurgical window-of-opportunity design, not overall survival, progression-free survival, or other time-to-event outcomes. The phase is described as Phase III dose selection but the trial itself is a presurgical study, not a definitive Phase III efficacy trial. | PMID 41628308PMC13001899 | 2026-Mar-20 | 0.95 | The study is an oncology randomized trial with a drug intervention and original results, but it does not have a primary or key secondary time-to-event efficacy endpoint. Its primary endpoints are pharmacodynamic (ER expression, Ki67) from a presurgical window-of-opportunity design, not overall survival, progression-free survival, or other time-to-event outcomes. The phase is described as Phase III dose selection but the trial itself is a presurgical study, not a definitive Phase III efficacy trial. | 无 KM 图 |
| Axitinib and Long-Acting Octreotide in Advanced Extrapancreatic Neuroendocrine Tumors: A Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trial (AXINET, GETNE 1107).J Clin OncolAI 判定该论文不进入自动 KM 提取:The study is explicitly described as a phase II/III trial, not solely a phase III trial. The primary endpoint was not met, but it does not meet the strict inclusion criteria of being a pure phase III randomized controlled trial. | PMID 41719493PMC13001903 | 2026-Mar-20 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Ivarmacitinib ointment in treatment of adults with mild-to-moderate atopic dermatitis: phase III of a randomized double-blind placebo-controlled phase II/III clinical trial.Br J DermatolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41317338无 PMCID | 2026-Mar-19 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Long-term protection of an inactivated enterovirus type 71 vaccine against hand, foot, and mouth diseases in children: a modelling study.VaccinePubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41650673无 PMCID | 2026-Mar-19 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Cluster randomised controlled trial for service delivery redesign of primary care for people with diabetes: study protocol.BMJ Open入排复审未纳入:方案论文未报告临床试验结果。 | PMID 41857847PMC13007129 | 2026-Mar-18 | 0.97 | 方案论文未报告临床试验结果。 | 无 KM 图 |
| Rapid and Sustained Response of Biochemically Uncontrolled Acromegaly to Once-daily Oral Paltusotine Treatment.J Clin Endocrinol Metab疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 7 张 PMC Figure,均未识别为 KM 图:Figure 1.:研究设计图;Figure 2.:图注未提示 KM 曲线;Figure 3.:图注未提示 KM 曲线;Figure 4.:图注未提示 KM 曲线;Figure 5.:图注未提示 KM 曲线;另有 2 张未列出。 | PMID 41128642PMC13016795 | 2026-Mar-17 | 0.90 | The study is a Phase III randomized trial of a drug for acromegaly, which is an endocrine disorder, not a human malignant neoplasm. Therefore, it is excluded on oncology grounds. Additionally, the primary endpoint is IGF-I normalization (binary) and changes in IGF-I levels (continuous), not a time-to-event efficacy endpoint like OS, PFS, DFS, EFS, RFS, TTP, or survival analysis with Kaplan-Meier/HR. | 无 KM 图 |
| Anal Human Papillomavirus Infection Progression to Disease Among Men Who Have Sex With Men.Clin Infect Dis疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 2 张 PMC Figure,均未识别为 KM 图:Figure 1.:非 KM 图;Figure 2.:非 KM 图。 | PMID 41162330PMC13016981 | 2026-Mar-17 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| Identification of tofersen PD-response biomarkers in VALOR clinical trial CSF via multiplexed quantitative proteomics.Cell Rep Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:Figure 1:图注未提示 KM 曲线;Figure 1:非 KM 图;Figure 2:图注未提示 KM 曲线;Figure 3:图注未提示 KM 曲线;Figure 4:图注未提示 KM 曲线。 | PMID 41850233PMC13006395 | 2026-Mar-17 | 0.95 | The study is a randomized Phase III trial of a drug intervention with original results, but it investigates amyotrophic lateral sclerosis (ALS), a neurodegenerative disease, not a human malignant neoplasm (cancer). Therefore, it is excluded from the oncology Kaplan-Meier cohort. | 无 KM 图 |
| INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.Clin Cancer ResAI 判定该论文不进入自动 KM 提取:The study is a combined Phase II/III trial with an adaptive design, and it was stopped early based on interim analysis, meaning it did not complete the Phase III portion as intended. | PMID 41427951PMC13012248 | 2026-Mar-16 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2 positive metastatic breast cancer: long term survival results from randomised phase 3 PHILA trial.BMJ | PMID 41839514PMC12990035 | 2026-Mar-16 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Efficacy and Safety of Bowel Cleansing with Mini S-Oral Sulfate Tablet versus the Conventional Oral Sulfate Tablet: A Prospective, Randomized, Investigator-Blinded, Multicenter, Noninferior, Phase 3 Trial.Gut Liver疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Fig. 1:图注未提示 KM 曲线;Fig. 2:图注未提示 KM 曲线;Fig. 3:非 KM 图。 | PMID 41306094PMC12989664 | 2026-Mar-15 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Patient-reported outcomes in NRG Oncology RTOG 1010: Phase 3 trial evaluating the addition of trastuzumab to trimodality treatment of HER2 overexpressing esophageal adenocarcinoma.Cancer已检查 3 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 2:AI 判定为 other;Figure 3:瀑布图。 | PMID 41808581PMC13321207 | 2026-Mar-15 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Pimicotinib versus placebo for tenosynovial giant cell tumour (MANEUVER): an international, randomised, placebo-controlled, phase 3 trial.LancetPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41796601无 PMCID | 2026-Mar-14 | 0.95 | The trial is a randomized Phase 3 oncology study with a drug intervention and reports primary efficacy results. However, the primary endpoint is objective response rate (ORR), which is not a time-to-event endpoint. The abstract does not report any time-to-event outcome (e.g., OS, PFS, DFS, EFS, RFS, TTP), Kaplan-Meier survival curves, or hazard ratios. Therefore, it does not meet the requirement for a time-to-event efficacy endpoint. | 无 KM 图 |
| Cadonilimab plus chemotherapy with or without bevacizumab as first-line treatment for advanced cervical cancer: subgroup analyses from the COMPASSION-16 phase 3 trial.Nat Commun | PMID 41826281PMC13128965 | 2026-Mar-14 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 部分完成 |
| A potential association of SLC2A9 variant rs7442295 with uric acid at baseline and in interaction with iloperidone.Pharmacogenomics J疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Fig. 1:图注未提示 KM 曲线;Fig. 2:图注未提示 KM 曲线;Fig. 3:图注未提示 KM 曲线。 | PMID 41826282PMC12987721 | 2026-Mar-13 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41358601无 PMCID | 2026-Mar-12 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Orca-T vs allogeneic hematopoietic stem cell transplantation (Precision-T): a multicenter, randomized phase 3 trial.Blood | PMID 41385341PMC13123417 | 2026-Mar-12 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Romiplostim versus Placebo for Chemotherapy-Induced Thrombocytopenia.N Engl J MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41812193无 PMCID | 2026-Mar-12 | 0.95 | The record describes a Phase III randomized trial in oncology patients with a drug intervention and an original result report. However, the primary efficacy endpoint is a binary outcome (proportion of patients with no chemotherapy dose modifications), not a time-to-event endpoint like OS, PFS, DFS, or HR. Therefore, it does not meet the specific requirement for a time-to-event efficacy endpoint. | 无 KM 图 |
| Camrelizumab plus CAPOX with camrelizumab based maintenance versus CAPOX alone as initial treatment for gastric or gastro-oesophageal junction adenocarcinoma: randomised phase 3 trial.BMJ | PMID 41819560PMC12980530 | 2026-Mar-12 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Efficacy and safety of vornorexant in Japanese patients with insomnia: a randomized, placebo-controlled phase 3 pivotal study.Sleep疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:Graphical Abstract:图注未提示 KM 曲线;Figure 1:图注未提示 KM 曲线;Figure 2:图注未提示 KM 曲线;Figure 3:图注未提示 KM 曲线。 | PMID 41001841PMC13017578 | 2026-Mar-11 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Use of concomitant G-CSF in maintaining efficacious dose and safe delivery of docetaxel in combination with darolutamide in ARASENS: A phase III study.Eur J CancerPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41655462无 PMCID | 2026-Mar-11 | 0.85 | The record describes a secondary or supportive analysis of a Phase III RCT, focusing on safety, dose intensity, and G-CSF use, without reporting any survival, progression, recurrence, or other efficacy outcomes relevant to the cohort. | 无 KM 图 |
| STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma.J Clin Oncol | PMID 41325560PMC12959603 | 2026-Mar-10 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Chemoradiation ± Atezolizumab in Limited-Stage Small Cell Lung Cancer: Results of NRG Oncology/Alliance LU005.J Clin Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:FIG A1.:森林图/亚组分析图;FIG A2.:森林图/亚组分析图;FIG 1.:CONSORT/入组流程图;FIG 2.:森林图/亚组分析图;FIG 3.:森林图/亚组分析图。 | PMID 41529214PMC12874332 | 2026-Mar-10 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Thromboembolic Events During Perioperative Therapy for Resectable and Borderline Resectable Pancreatic Cancer in the PREOPANC-2 Trial.J Clin Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41610374无 PMCID | 2026-Mar-10 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Ustekinumab therapy for moderately to severely active pediatric Crohn's disease: UNITI Jr study safety and efficacy results in patients weighing at least 40 kg.J Crohns Colitis疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:Graphical Abstract:图注未提示 KM 曲线;Figure 1.:图注未提示 KM 曲线;Figure 2.:图注未提示 KM 曲线;Figure 3.:图注未提示 KM 曲线;Figure 4.:图注未提示 KM 曲线。 | PMID 41843763PMC13017028 | 2026-Mar-10 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| A Subgroup Analysis of Perioperative Pembrolizumab in Clinical Stage II Non-Small-Cell Lung Cancer from the Randomized KEYNOTE-671 Study.Eur J Cardiothorac Surg | PMID 41875364PMC13020334 | 2026-Mar-10 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 已完成 |
| A prospective external validation of the GRade, Age, Nodes and Tumor score in the ECOG-ACRIN EA8143 PROSPER trial.Oncologist | PMID 41693026PMC12978424 | 2026-Mar-09 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Randomized, Double-Blind, Multicenter, Phase 3 Study of AG NPP709 Compared With Ivy Leaf Extract in Patients With Acute or Chronic Respiratory Symptoms.J Korean Med Sci疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Fig. 1:图注未提示 KM 曲线;Fig. 2:图注未提示 KM 曲线;Fig. 3:图注未提示 KM 曲线。 | PMID 41807028PMC12976630 | 2026-Mar-09 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Predictors of Skeletal-Related Events and Quality-of-Life Dimensions Among Patients With High-Risk Asymptomatic Bone Metastases With or Without Early Radiation Therapy: Secondary Analysis of a Multicenter Randomized Phase II Clinical Trial.J Natl Compr Canc Netw入排复审未纳入:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | PMID 41825136无 PMCID | 2026-Mar-09 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| Safety, immunogenicity, and lot consistency of a 13-valent pneumococcal conjugate vaccine in Chinese children aged 2-5 years: A phase III study.VaccinePubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41554243无 PMCID | 2026-Mar-07 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| 5-year results of hypofractionated locoregional radiotherapy in early breast cancer HypoG-01 (UNICANCER): a French multicentre, randomised, non-inferiority, phase 3, open-label, controlled trial.LancetPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41794436无 PMCID | 2026-Mar-07 | 0.85 | The trial is a Phase III randomized oncology study with a primary time-to-event endpoint, but the intervention compares two radiotherapy fractionation schedules without a drug-containing arm, failing the drug intervention criterion. | 无 KM 图 |
| Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trial.LancetPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41794437无 PMCID | 2026-Mar-07 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| CPX-351 vs daunorubicin, cytarabine, and gemtuzumab ozogamicin in older adults with non-adverse-risk AML: the NCRI AML18 trial.Blood疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 6 张 PMC Figure,均未识别为 KM 图:Figure 1:非 KM 图;Figure 1.:非 KM 图;Figure 2.:CONSORT/入组流程图;Figure 3.:非 KM 图;Figure 4.:森林图/亚组分析图;另有 1 张未列出。 | PMID 41237344PMC13052346 | 2026-Mar-05 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Finerenone in Type 1 Diabetes and Chronic Kidney Disease.N Engl J MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41780000无 PMCID | 2026-Mar-05 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Neoadjuvant GOLP in Resectable High-Risk Intrahepatic Cholangiocarcinoma.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41780001无 PMCID | 2026-Mar-05 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Clinical evaluation of the efficacy and safety of nasturtium herb and horseradish root versus placebo in the continuous prophylaxis of recurrent uncomplicated cystitis: a double-blind randomised clinical trial.BMC Complement Med Ther疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Fig. 1:CONSORT/入组流程图;Fig. 2:ROC 图;Fig. 3:非 KM 图。 | PMID 41782129PMC13063873 | 2026-Mar-05 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Imipenem/cilastatin/relebactam dosing regimen justification using exposure-efficacy analyses in participants with hospital-acquired bacterial pneumonia or ventilator-associated bacterial pneumonia in the RESTORE-IMI 2 phase 3 study.Antimicrob Agents Chemother已检查 4 张 PubMed Figure,均未识别为 KM 图:Fig 1:AI 判定为 flow diagram;Fig 2:AI 判定为 other;Fig 3:AI 判定为 other;Fig 4:AI 判定为 other。 | PMID 41586496PMC12959156 | 2026-Mar-04 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Once-weekly somapacitan in children with Noonan syndrome: randomized controlled phase 3 trial.Eur J EndocrinolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41774755无 PMCID | 2026-Mar-04 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Somapacitan in children born small for gestational age: a randomized controlled phase 3 trial.Eur J EndocrinolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41782416无 PMCID | 2026-Mar-04 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Bellmunt Risk Score as a Prognostic Tool in Metastatic Castration-Resistant Prostate Cancer Survival.JAMA Netw Open入排复审未纳入:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | PMID 41790469PMC12966927 | 2026-Mar-02 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| Bayesian Statistics to Reanalyze Data From the STAAMP Trial.JAMA Netw Open疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41842893无 PMCID | 2026-Mar-02 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Long-Term Outcomes of Concurrent Chemoradiotherapy With S-1 in Older Patients With Esophageal Cancer: A Secondary Analysis of a Randomized Clinical Trial.JAMA Netw Open | PMID 41893843PMC13032157 | 2026-Mar-02 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 已完成 |
| Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable HCC: HIMALAYA phase III randomized clinical trial.Hepatology | PMID 40384092PMC12904228 | 2026-Mar-01 | 0.96 | 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 | 已完成 |